5 Value Stocks To Watch In The Communication Services Sector

The Meaning Behind Value Stocks A value stock traditionally has a lower price when compared to stock prices…

The Meaning Behind Value Stocks

A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be undervalued, as investors are not expressing as much interest in such companies. The most commonly used way to check for value is with the price-to-earnings multiple, or P/E. A low P/E multiple is a good indication that the stock is undervalued.

Below is a list of notable value stocks in the communication services sector:

  1. Verizon Communications (NYSE:VZ) – P/E: 6.69
  2. Liberty SiriusXM Gr (NASDAQ:LSXMA) – P/E: 8.8
  3. Liberty SiriusXM Gr (NASDAQ:LSXMK) – P/E: 8.9
  4. Steel Connect (NASDAQ:STCN) – P/E: 7.55
  5. Sphere Entertainment (NYSE:SPHR) – P/E: 7.09

This quarter, Verizon Communications experienced an increase in earnings per share, which was $1.2 in Q1 and is now $1.21. Most recently, the company reported a dividend yield of 7.78%, which has increased by 0.45% from last quarter’s yield of 7.33%.

Most recently, Liberty SiriusXM Gr reported earnings per share at $0.08, whereas in Q1 earnings per share sat at $0.06. Liberty SiriusXM Gr’s earnings per share for Q2 sits at $0.08, whereas in Q1, they were at 0.38. Steel Connect saw an increase in earnings per share from -0.19 in Q2 to $0.37 now. This quarter, Sphere Entertainment experienced an increase in earnings per share, which was $-1.55 in Q3 and is now $10.21.

The Significance: A value stock may need some time to rebound from its undervalued position. The risk of investing in a value stock is that this emergence may never materialize.

Total
0
Shares
Related Posts
Read More

BriaCell To Host Virtual Key Opinion Leader Event On Bria-IMT Potential In Advanced Metastatic Breast Cancer On October 26, 2023 Featuring Dr. Adam M. Brufsky From University Of Pittsburgh School Of Medicine And Dr. Saranya Chumsri From Mayo Clinic

Dr. Adam M. Brufsky of University of Pittsburgh School of Medicine and Dr. Saranya Chumsri of Mayo Clinic will discuss the current treatment landscape for patients with advanced metastatic breast cancer and the latest

BCTX

Read More

Matinas BioPharma Announces Interim Data From The Phase 2 EnACT Trial Of MAT2203 For The Treatment Of Cryptococcal Meningitis, Exceeding Primary Endpoint Threshold; Patient Survival In All-Oral Cohort 4 Regimen Currently 90%

Two-week survival in Cohort 4 (all-oral regimen) was 95% in 40 patients receiving MAT2203     Mean Early Fungicidal Activity (EFA) of the rate of yeast clearance in cerebrospinal fluid exceeded

MTNB